The improvement of the sensitivity anf the precision of the cfDNA techniques allowed the unique opportunity of monitoring in the time during treatment the genomic profiling of prostate cancer patients undergoing treatment with AR antagonists. This evidence concerns the gene AR and prostate carcinoma.